Answers are grounded in this paper and cite their sources.
Evaluate the efficacy and safety of ANX005 compared to placebo in Guillain-Barré syndrome (GBS) patients.
No takes yet. Share an insight, caveat, or question.
Kroon et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: